Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab vs Investigator's Choice in Relapsed/Refractory Multiple Myeloma
NCT06152575Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Feb 2024
- Primary completion
- Aug 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of elranatamab in multiple myeloma (MM), sponsored by Pfizer. Started Feb 2024; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06152575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06152575.